Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 3/2011

01-06-2011

Androgen Suppression Strategies for Prostate Cancer: Is There an Ideal Approach?

Authors: Mohamed Ismail, Matthew Ferroni, Leonard G. Gomella

Published in: Current Urology Reports | Issue 3/2011

Login to get access

Abstract

Androgen suppression therapy (AST) was first described in 1941 as a treatment of prostate cancer (PCa) and remains the mainstay of therapy in patients with hormone-naïve metastatic disease. It also is used in locally advanced or recurrent disease and in combination with radiation therapy in patients with higher-risk features. Several approaches to AST have been developed as a result of increased understanding of the pathways controlling testosterone production. Increased recognition of the side effects has resulted in strategies to minimize complications associated with AST. Attempts to reduce AST adverse effects include intermittent hormonal therapy and methods to reduce amount of intracellular androgens without reducing the circulating testosterone levels.
Literature
1.
2.
Collette L, Struder U, Iversen P, et al. Is the degree of PSA decline after immediate androgen deprivation a prognostic factor for outcome in patients with T0-4, N0, M0 prostate cancer not suitable for local treatment with curative intent? Paper presented at: 21st Congress of the European Association of Urology; April 5–8, Paris, France: 2006.
3.
Bolla M, Collette L, Blank L, et al. Long term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer: a phase III randomized trial. Lancet. 2002;360:103–6.PubMedCrossRef
4.
Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long term results of phase III RTOG 85–31. Int J Radiat Oncol Biol Phys. 2005;61:1285–90.PubMedCrossRef
5.
Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86–10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243–52.PubMedCrossRef
6.
Denham JW, Steigler A, Lamb DS, et al. Short term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology group 96.01 randomized controlled trial. Lancet Oncol. 2005;6:841–50.PubMedCrossRef
7.
•• Nguyen PL, Chen MH, Beard CJ, et al. Radiation therapy with or without 6 months of androgen suppression therapy in intermediate-and high risk clinically localized prostate cancer: a postrandomization analysis by risk group. Int J Radiat Oncol Biol Phys. 2010;77(4):1046–52. This article demonstrates that the risks of adjuvant AST outweigh its benefits in patients with high comorbidities.PubMedCrossRef
8.
D’Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25:2420–5.PubMedCrossRef
9.
Roach M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external—beam radiotherapy for locally advanced prostate cancer: long term results of RTOG 8610. J Clin Oncol. 2008;26:585–91.PubMedCrossRef
10.
•• Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen suppression therapy for locally advanced prostate cancer: RTOG 85–31. J Clin Oncol. 2009;27:92–9. This article demonstrates that the benefits of AST outweigh its risks in locally advanced prostate cancer.PubMedCrossRef
11.
Seidenfled J, Samson DJ, Hassellad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and metanalysis. Ann Intern Med. 2000;132:566–77.
12.
Thompson IM, Zediman EJ, Rodriguez FR. Sudden death due to disease flare with luteinizing hormone-releasing hormones agonist therapy for carcinoma of the prostate. J Urol. 1990;144:1479–80.PubMed
13.
• Heidenreich H, Aus G, Bolla M, et al. European Association of Urology: EUA guidelines on prostate cancer. Eur Urol. 2008;53:68–80. This article reviews the guidelines recommend by the European Association of Urology in management of prostate cancer.PubMedCrossRef
14.
Zinner NR, Bidair M, Ceneteno A, et al. Similar frequency of testosterone surge after repeat injection of goserelin (zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial. Urology. 2004;64:1177–81.PubMedCrossRef
15.
•• Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531–8. After the results of this study, degarelix was granted FDA approval.PubMedCrossRef
16.
Iversen P, Tammela TLJ, Vaage S, et al. A randomized comparison of Bicalutamide (Casodex) 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard of care for early non-metastatic prostate cancer. First report from the Scandinavian Prostate Cancer Group study No. 6. Eur Urol. 2002;42:204–11.PubMedCrossRef
17.
Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Lancet. 2010;375(9724):1437–46.PubMedCrossRef
18.
Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trails. Lancet. 2000;355:1036–42.
19.
• Nanda A, Chen MH, Moran AJ, et al. Total androgen blockage versus luteinizing hormone-releasing hormone agonist alone in men with high risk prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2010;76(5):1439–44. This study demonstrated that radiation therapy and MAB is superior to monotherapy in the adjuvant setting.PubMedCrossRef
20.
D’Amico AV, Chen MH, Renshaw AA, et al. Risk of prostate cancer recurrence in men treated with radiation alone or in conjugation with combined or less than combined androgen suppression therapy. J Clin Oncol. 2008;26:1036–42.
21.
Presti JC, Fair WR, Andriole G, et al. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (mK-906) on stage D prostate cancer. J Urol. 1992;148:1201–4.PubMed
22.
Andriole G, Lieber M, Smith J, et al. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology. 1995;45:491–7.PubMedCrossRef
23.
Barqawi AB, Moul JW, Bittman L, et al. Combination of low dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. Urology. 2003;62:872–6.PubMedCrossRef
24.
Oh WK, Manola J, Bittman L, et al. Finasterdie and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology. 2003;62:99–105.PubMedCrossRef
25.
Shah SK, Trump DL, Sarto O, et al. Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol. 2009;181:621–6.PubMedCrossRef
26.
Boustead G, Edwards SJ. Systemic review of early versus deferred hormonal treatment of locally advanced prostate cancer; a metanalysis of randomized controlled trials. BJU Int. 2007;99:1383–9.PubMedCrossRef
27.
Spiess PE, Lee AK, Denham, et al. Surgically managed lymph node-positive prostate cancer; does delaying hormonal therapy worsens the outcome? BJU Int. 2007;99:321–5.PubMedCrossRef
28.
Tenenholz TC, Shields C, Ramesh R, et al. Survival benefit for early hormone ablation in biochemically recurrent prostate cancer. Urol Onc. 2007;25:101–9.CrossRef
29.
Moul JW, Wu H, Sun L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004;171:1141–7.PubMedCrossRef
30.
Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally danced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295–300.PubMedCrossRef
31.
The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostate cancer: initial results of the Medical Research Council Trial. Br J Urol. 1997;79:235–46.
32.
Studer UE, Hauri D, Hanselmann S, et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment; results of the randomized trial SAKK 08/88. J Clin Oncol. 2004;22:4109–18.PubMedCrossRef
33.
•• Bolla M, de Reike TM, Tienhoven GV, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360:2516–27. This study established prolonged AST as the standard of care in patients with locally advanced disease.PubMedCrossRef
34.
Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of Radiation Therapy Oncology Group protocol 92–02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26:2497–504.PubMedCrossRef
35.
D’Amico AV, Manola J, Loffredo M, et al. 6 months androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled study. JAMA. 2004;292:821–7.PubMedCrossRef
36.
• Choo R, Danjoux C, Gardner S, et al. Efficacy of salvage radiotherapy plus 2 years androgen suppression for postradical prostatectomy patients with PSA relapse. Int J Radiat Oncol Biol Phys. 2009;75(4):983–9. This study demonstrated a benefit from addition of AST to radiation therapy in patients with PSA relapse after RP.PubMedCrossRef
37.
• Choo R, Danjoux C, Gardner S, et al. Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins. Int J Radiat Oncol Boil Phys. 2009;75(2):407–12. This study demonstrated a benefit form addition of AST to radiation therapy in patients with pT3 and/or positive margins after RP.CrossRef
38.
Bhandari MS, Crook J, Hussain M. Should intermittent androgen deprivation be used in routine clinical practice? J Clin Oncol. 2005;23:8212–8.PubMedCrossRef
39.
Shaw GL, Wilson P, Cuzick J, et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1,446 patients. BJU Int. 2007;99:1056–65.PubMedCrossRef
40.
•• Abrahamasson PA. Potental benefits of intermittent androgen suppression therapy in treatment of prostate cancer: a systemic review of the literature. Eur Urol. 2010;57:49–59. This article reviews the benefits of phase 2 and 3 studies of IHT to date.CrossRef
41.
Crook JM, Szumacher E, Malone S, et al. Intermittent androgen suppression in the management of prostate caner. Urology. 1999;53:530–4.PubMedCrossRef
42.
de Leval J, Boca P, Yousef E, et al. Intermittent versus continuous total androgen blockade in treatment of patients with advanced hormone-naïve prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer. 2002;1:163–71.PubMed
43.
Prapotnich D, Cathelineau X, Rozet F, et al. A 16 year clinical experience with intermittent androgen deprivation for prostate cancer. Oncological results. World J Urol. 2009;27:627–35.PubMedCrossRef
44.
Gleave M, Klotz L, Taneja SS. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer. Urol Oncol. 2009;27:81–6.CrossRef
45.
Rosner W, Vesper HJ. Toward excellence in testosterone testing: a consensus statement. Clin Endocrinol Metab. 2010;95:4542–8.CrossRef
46.
Morote J, Planas J, Raventos CX, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol. 2007;178:1290–5.PubMedCrossRef
47.
Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormones (LHRH) agonists: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol. 2000;164(3):726–9.PubMedCrossRef
48.
Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447–54.PubMedCrossRef
49.
Shah S, Ryan C. Abiraterone acetate for castration resistant prostate cancer. Expert Opin Investig Drugs. 2010;19(4):563–70.PubMedCrossRef
50.
•• Kim HS, Freedland SJ. Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management. Curr Opin Supp Care. 2010;4:147–52. This article reviews all the complications associated with AST. The recommended management for these complications is reviewed.CrossRef
Metadata
Title
Androgen Suppression Strategies for Prostate Cancer: Is There an Ideal Approach?
Authors
Mohamed Ismail
Matthew Ferroni
Leonard G. Gomella
Publication date
01-06-2011
Publisher
Current Science Inc.
Published in
Current Urology Reports / Issue 3/2011
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-011-0178-0

Other articles of this Issue 3/2011

Current Urology Reports 3/2011 Go to the issue

ReviewPaper

Quality of Evidence to Compare Outcomes of Open and Robot-Assisted Laparoscopic Prostatectomy

ReviewPaper

Use of Testosterone Replacement Therapy in Patients with Prostate Cancer

ReviewPaper

Complications of Pelvic Lymph Node Dissection for Prostate Cancer

ReviewPaper

Update on Prostate Brachytherapy: Long-term Outcomes and Treatment-related Morbidity

ReviewPaper

Management of Rising Prostate-specific Antigen After a Negative Biopsy

ReviewPaper

Current Perspectives on Gleason Grading of Prostate Cancer